Almac Group Launches Almac Adapt™ – a New Patient-Centric Supply Solution

Innovative Just in Time Manufacturing (JTM) enables sponsors full late stage customisation of their clinical trial materials

Craigavon, N.I., 13 June 2019Almac Clinical Services, part of the Almac Group, has today announced the launch of Almac Adapt™ – an innovative Just in Time Manufacturing (JTM) solution.  This latest offering puts patients first and provides sponsors with a unique, adaptive supply strategy to ultimately meet the expanding challenges of clinical trials.
Read More

Thank you to our members who continue to support the Chamber through their membership, you make our mission possible!

Renewing members in May and June (to date):

Mid-Size Firms:
TMC Consulting, Tom McCool
Kent/McBride, PC, John Kent
PA DCED, Joe Burke and Michael O’Rourke

Individual Members
Thomas Killeen, Toppan Merrill
Thomas Ivory, Law Office of Thomas Ivory
Ralph Kelly, McShea Law Firm
Francis McGee, The McGee Group
James R. Malone, Jr., Post & Schnell
Peter McGrath, Corriendo LLC

Almac Group Reports Further Growth During Period of Significant Global Expansion

2017-18 figures record turnover increased by £17 million with 8% growth in global workforce

Craigavon, N.I., 03 Jun 2019 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, has reported a £17 million rise in turnover from £531 million to £548 million for 2017-18.  Pre-tax profits were recorded at £27 million whilst average employee figures increased by 8% from 4,407 to 4,798 for the same period. The figures were recorded in Almac’s annual report with its results for the year ending 30 September 2018.
Read More

Spark CEO Marrazzo: Philadelphia will shine at BIO 2019
By Jeff Marrazzo – Guest Columnist
Philadelphia Business Journal

Our region is a hotbed for gene and cell therapy innovation. How do we mazimize this moment?

Thousands of biotech leaders, researchers and entrepreneurs are in Philadelphia this week at the BIO International Convention. While there will be a myriad of discussions about the latest industry developments and breakthroughs, one of the more compelling stories will be the rise of Philadelphia as the hotbed for gene and cell therapy innovation and the potential for the city to capitalize on this moment to sustain its position as the leader in genetic medicine — the future of healthcare.

Read More